Summary A previously described mathematical model designed to evaluate resistance and tumour-kill for individual patients, and to predict changing tumour sizes, has been applied to patients with small cell lung cancer. The model requires tumour volume measurements, and these were obtained via computed tomography scans of the chest. The model fitted the data well, and was able to predict later tumour volumes using earlier ones, as well as suggesting times at which to change or abandon treatment for individual patients. The model gave estimates for resistance and tumour-kill which may provide additional useful outcome measures for clinical trials, and help in the design of future studies.
The standard measures of success in clinical trials, namely differences in response rates, response duration or survival, although essential, yield little information as to why a particular regime fares better, or by what means prognosis is improved. Consequently the rationale for proceeding from one trial to the next is often unclear, many trials are needed to establish the principles on which development may take place, and trials often seem to produce contradictory results (Slevin & Staquet, 1986) .
Attempts have been made, in recent years, to explain and interpret results from clinical trials in terms of resistance to and efficacy of chemotherapy, and differences in tumour growth rates using mathematical models (Birkhead & Gregory, 1984; Birkhead et al., 1986; Goldie & Coldman, 1979; Skipper & Perry 1970) . Such models, it is hoped, will provide meaningful explanations for trial differences, improving the speed and direction of research.
The models of Goldie & Coldman (1979) and Skipper & Perry (1970) espouse general principles, such as the alternating of non-cross-resistant drug combinations. A model has also been developed for individual patients (Birkhead & Gregory, 1984; Birkhead et al., 1986) . It was thought that, once validated, such a model might enable results to be achieved on smaller numbers of patients, since the additional interpretative information ought to improve the power of any tests used. An attempt is made to validate this model on patients with small cell lung cancer (SCLC) . The model requires an accurate method of measuring tumour volumes, and computerised tomography (CT) scans of the chest have been employed to this end. Having estimated the resistance to and efficacy of chemotherapy, and the tumour growth rate, the model predicts the sequence of tumour volumes before each course of chemotherapy. The validity and accuracy of these predictions were tested on a series of up to seven scans on each of nine patients with SCLC. supply and the likely stochastic nature of cell-killing by cytotoxic agents. The tumour growth rate is empirically assumed to be exponential for the period of therapy, and it is assumed that throughout the treatment period the mutation rate from sensitivity to resistance or vice versa is negligible in comparison to the other effects.
The proportion of sensitive tumour killed by each cycle of the treatment is assumed to be the same (Skipper & Perry, 1970) , and is represented by k. The proportion of tumour initially resistant is represented by R. The tumour doubling time is denoted by d. The model predicts, for particular values of these three independent variables, k, Ro and d, given the above assumptions, the sequence of tumour volumes before each treatment cycle (Birkhead & Gregory, 1984) , as shown in the Appendix. Table I , and shown diagrammatically in Figures 2 and 3 . Patients with peripheral masses on chest X-ray were chosen for the study since it was possible to separate tumour from mediastinal structures on the scans in these patients. The patients were scanned on a GE 9800 Whole Body Scanner. Scans were performed at 1 cm intervals throughout the region of the tumour. Where necessary, a bolus of intravenous contrast medium was administered to delineate vascular structures. The area of the lesion was then calculated on each image using a tracing device. As the scan thickness was I cm in each image the volume could be easily estimated. Care was taken to avoid measuring areas of lung consolidation or collapse, although this was not always possible. Where such discrimination was difficult in a series of scans a special effort was made to measure the same structures on each scan in the series. However, the initial measurements in this series were often made as the scans became available, several weeks apart.
One patient died during therapy and consequently has only three tumour volumes recorded; the rest have at least four, generally five, and in one case seven tumour volumes measured.
Methods
In order to estimate the model's parameters, i.e. the proportion of sensitive tumour killed with each cycle of therapy, k, the resistance at presentation Ro, and the tumour doubling time d, four tumour volumes are required. Hence the model could only be applied to eight of the nine patients.
With only four volumes, if the model fits the observed data at all, it will fit exactly, since all four volumes will be needed to estimate the parameters (given four tumour volumes, equation (1) in the Appendix will generate three equalities, just sufficient to derive values for the three independent parameters, k, Ro and d). If the model is not a reasonable representation of the actual diseases processes, it may be expected that no values of the parameters would be capable of predicting the observed volumes. For instance, if the percentage tumour reduction on the first cycle of treatment was less than that seen on the second cycle (assuming a similar interval between cycles) the model would be invalid. With more than four tumour volumes the accuracy of the model can be evaluated, assuming the model fits at all, as just explained, since its consistency in predicting the sequential tumour volumes can be examined. In these cases (six of the nine patients), all the tumour volumes were used to estimate the model's parameters. The model can then be validated by a x2 test comparing the observed tumour volumes with those expected under the model assumptions.
Supposing k, R. and d were known, some slight differences would still be expected between the model predictions and the actual tumour volumes, due to inaccuracies in measurement, i.e. the variations in marking out the area of tumour or delineating the tumour from other structures, as well as collapse and consolidation within the tumour. Hence in order to estimte k, Ro and d, a normal distribution of errors about these predictions has been assumed, the mathematics of which is given in the Appendix. Table  IV . Initially, a guess is made for the values of the parameters (see Table IV therapy. At present such information is only obtained from randomised trials addressing these questions, and then only by interpretation from the gross outcome measures of response duration and survival. The method described in this report enables these factors to be estimated for individual patients, and thus the effects of the treatments can be more easily evaluated. Table V .) The model detected that this lessening of the tumour-kill presaged rapid re-growth. This would have been the moment to stop treatment, or switch to a possibly non-cross-resistant alternative.
Alternative models (e.g. Birkhead et al., 1987) can be considered where a proportion of the tumour is non-dividing, due, for example, to lack of vascularisation. However, this assumption was considered unnecessary, and was thought to add needless complexity in SCLC. In this tumour the monoclonal antibody Ki67, which stains cells not in the GO phase of the cell cycle, suggests that 60% or more of the cells are in cycle at any one time (Gatter et al., 1986) .
The reproducibility of the tumour volumes, especially where identical structures can be measured on each occasion, appears in this study to be good, and certainly sufficient to enable estimation of the model parameters. The model appears to predict the data fairly accurately, with the average standard deviation of errors in volume being approximately 9%.
It is interesting to note that, with the exception of patient 7, there appears to be a relationship between k, the tumourkill, and d, the doubling time (r = -0.89, P = 0.004). This seems intuitively reasonable, with therapy being more effective on rapidly dividing tumours. It may be that the course 5 and 6 volumes for patient 7 represent non-dividing cells, as described.
It is likely that the doubling time of a tumour reflects a balance between the rate at which the cells are proliferating and the rate of cell loss. This would not significantly affect the model's estimates or validity, since it makes assumptions only about the gross tumour volume. It may, however, help to reconcile the relatively slow doubling time estimated by the model with the large proportion of dividing cells found with the monoclonal antibody Ki67, and with the relatively high cell-kills estimated and presented in Table III .
It is interesting that a wide variability in proportions of initially resistant tumour was seen, as suggested by Goldie & Coldman (1982) , using a model where resistance is acquired by spontaneous mutation.
Cancers other than SCLC, with tumour markers, may provide better applications for this model. However, since SCLC is a highly chemosensitive tumour, alterations in dose and schedule provide hope of significant, and sorely needed, improvements. In another application, this model helped to explain why high-dose cyclophosphamide failed to cure more patients with SCLC (Gregory et al., 1988) . Such explanations may aid in the design of new and better protocols.
Appendix
The model predicts that sequential tumour volumes before treatment (A0, XI, X2, ..., X.,) will be described by the equation:
XiI-a-(I-a )ko Xoei (i = 1, 2, n) (1) where a = (1-k), ko = k(l -RO), k is the proportion of the sensitive tumour killed with each course of therapy, Ro is the proportion of the tumour initially resistant, a is the (exponential) growth rate, t, is the time between first treatment and treatment cycle i + 1, and i is the treatment cycle number itself.
From equation (1) log Xi= log [ ja) (I I) + log XO + ati (2) Let the actual tumour volumes tumours be VO, VI, ..., Vn.
Since the tumour is growing exponentially, and large errors are more likely when measuring large tumours, it will be assumed that errors in measurement of these volumes are log-normally distributed about the model's predictions (equation 2) with some constant standard deviation a (this is equivalent to the assumption that the same percentage error can be expected at each tumour volume).
Then the likelihood of the (log of) the volumes under the model, L, is L(log VO, log V, log V.) = N(log VO, log XO, oa).
N(log V,, log XI, x) ... N(log V., log Xn, ax) n =7T N(log Vi, log Xi, (x) i=O where N(x, u, a) is the value ofa normal distribution with mean u and variance a at x.
Hence n log L = E log N(log VJ, log Xi, ax) 
